Cubist Hopes For A Blockbuster Antibiotic With In Acquisition Of Calixa
This article was originally published in The Pink Sheet Daily
Executive Summary
Cubist pays $92.5 million upfront for a private biotech and its lead programs, hoping to find a complementary product for Cubicin.